Role of a second transplantation for children with acute leukemia following posttransplantation relapse: a study by the Turkish Bone Marrow Transplantation Study Group
Makaleler > Tam Makale · 2020
Yazarlar: Volkan Hazar, Gulsun Tezcan Karasu, Vedat Uygun, Namik Ozbek, MUSA KARAKÜKCÜ, Gulyuz Ozturk, Hayriye Daloglu, Suar Caki Kilic, TEKİN AKSU, EKREM ÜNAL, Ulker Kocak, Akif Yesilipek, Arzu Akcay, Orhan Gursel, Alphan Kupesiz, FATMA VİSAL OKUR, Talia Ileri, Savaş KANSOY, İBRAHİM BAYRAM, Barbaros Sahin Karagun, Muge Gokce, Zuhre Kaya, Ikbal Ok Bozkaya, Turkan Patiroglu, Serap AKSOYLAR
LEUKEMIA & LYMPHOMA, SCI Expanded İndekslerine Giren Dergi, Uluslararası, 2020, cilt 61, ss 1465-1474
DOI: 10.1080/10428194.2020.1716220
Özet
We examined outcomes of 51 pediatric patients with relapsed acute leukemia (AL) who underwent a second allogeneic hematopoietic stem cell transplantation (alloHSCT). After a median follow-up of 941 days (range, 69-2842 days), leukemia-free survival (LFS) and overall survival (OS) at 3 years were 26.6% and 25.6%, respectively. The nonrelapse mortality rate (NMR) and cumulative incidence of relapse (CIR) were 36.4% and 42.4%, respectively. The Cox regression analysis demonstrated that the risk factors at second transplantation for predicting limited LFS were active disease (hazard ratio (HR) = 5.1), reduced intensity conditioning (RIC) (HR = 5.0), matched unrelated donor (MUD) (HR = 3.4) and performance score <80 (HR = 3.2). Pediatric patients with AL who relapsed after their first alloHSCT may survive with a second alloHSCT. Disease status, conditioning intensity, donor type, and performance score at the second transplantation are the relevant risk factors. A score based on these factors may predict the results of the second transplantation.